The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.
[EN] FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZINE FUSIONNÉS EN TANT QU'INHIBITEURS DE KINASE
申请人:UCB PHARMA SA
公开号:WO2010052448A3
公开(公告)日:2010-09-10
[EN] SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF<br/>[FR] 5-AMINOPYRAZOLES SUBSTITUÉS ET LEUR UTILISATION
申请人:BAYER SCHERING PHARMA AG
公开号:WO2010020363A1
公开(公告)日:2010-02-25
The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.
[EN] UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS<br/>[FR] DÉRIVÉS D'URÉE UTILISÉS EN TANT QU'ACTIVATEURS DE LA PYRUVATE KINASE
申请人:GLOBAL BLOOD THERAPEUTICS INC
公开号:WO2022031735A1
公开(公告)日:2022-02-10
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.